Advertisement

Recent Advances in the Management of Idiopathic Intracranial Hypertension (IIH)

  • Virender SachdevaEmail author
  • Gurcharan Singh
  • Gautam Yadav
Chapter
Part of the Current Practices in Ophthalmology book series (CUPROP)

Abstract

Idiopathic intracranial hypertension is a complex disorder and is still an enigma for most neuro-ophthalmologists. This chapter aims to try to demystify this disease to the extent possible by discussing the latest literature with regard to the epidemiology of the disease, relevant terminology, and diagnostic criteria. It also explains the clinical findings and investigations including neuroimaging and the classical signs and their relevance in diagnosing IIH. Management of the disease in also discussed in detail including medical and surgical options and newer advances such as bariatric surgery. Treatment of IIH in special situations such as IIH in pregnancy and pediatric IIH is explained. The chapter also covers latest developments in understanding the pathophysiology of the disease and current research on the subject.

Keywords

Papilledema Idiopathic intracranial hypertension MRI Acetazolamide Optic nerve sheath fenestration 

References

  1. 1.
    Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology. 2002;59:1492–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Gibby WA, Cohen MS, Goldberg HI, Sergott RC. Pseudotumor cerebri: CT findings and correlation with vision loss. Am J Roentgenol. 1993;160:143–6.CrossRefGoogle Scholar
  3. 3.
    Brodsky MC, Vaphiades M. Magnetic resonance imaging in pseudotumor cerebri. Ophthalmology. 1998;105:1686–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Beri S, Gosalakkal JA, Hussain N, et al. Idiopathic intracranial hypertension without papilledema. Pediatr Neurol. 2010;42:56–8.PubMedCrossRefGoogle Scholar
  5. 5.
    De Simone R, Ranieri A, Fiorillo C, Bilo L, Bonavita V. Is idiopathic intracranial hypertension without papilledema a risk factor for migraine progression? Neurol Sci. 2010;31:411–5.PubMedCrossRefGoogle Scholar
  6. 6.
    De Simone R, Ranieri A, Montella S, Marchese M, Bonavita V. Sinus venous stenosis-associated idiopathic intracranial hypertension without papilledema as a powerful risk factor for progression and refractoriness of headache. Curr Pain Headache Rep. 2012;16:261–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Markey KA, Mollan SP, Jensen RH, Sinclair AJ. Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurol. 2016;15:78–91.PubMedCrossRefGoogle Scholar
  8. 8.
    Johnston I, Owler B, Pickard J. The pseudotumor cerebri syndrome: pseudotumor cerebri, idiopathic intracranial hypertension, benign intracranial hypertension and related conditions. Cambridge: Cambridge University Press; 2007. p. 1–356.CrossRefGoogle Scholar
  9. 9.
    Friedman D, Liu GT, Digre K. Revised diagnostic criteria for pseudotumor cerebri in adults and children. Neurology. 2013;81:1159–65.PubMedCrossRefGoogle Scholar
  10. 10.
    Craig JJ, Mulholland DA, Gibson JM. Idiopathic intracranial hypertension; incidence, presenting features and outcome in Northern Ireland (1991–1995). Ulster Med J. 2001;70:31–5.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Radhakrishnan K, Thacker AK, Bohlaga NH, Maloo JC, Gerryo SE. Epidemiology of idiopathic intracranial hypertension: a prospective and case-control study. J Neurol Sci. 1993;116:18–28.PubMedCrossRefGoogle Scholar
  12. 12.
    Raoof N, Sharrack B, Pepper IM, Hickman SJ. The incidence and prevalence of idiopathic intracranial hypertension in Sheffield, UK. Eur J Neurol. 2011;18:1266–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Kesler A, Gadoth N. Epidemiology of idiopathic intracranial hypertension in Israel. J Neuroophthalmol. 2001;21:12–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Durcan FJ, Corbett JJ, Wall M. The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana. Arch Neurol. 1988;45:875–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Radhakrishnan K, Ahlskog JE, Cross SA, Kurland LT, O’Fallon WM. Idiopathic intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol. 1993;50:78–80.PubMedCrossRefGoogle Scholar
  16. 16.
    Wall M, Kupersmith MJ, Kieburtz KD, Corbett JI, Feldon SE, Friedman DI, NORDIC Idiopathic Intracranial Hypertension Study Group, et al. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol. 2014;71:693–701.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Ambika S, Arjundass D, Noronnha V, Anshuman. Clinical profile, evaluation, management and visual outcome of idiopathic intracranial hypertension in a neuro-ophthalmology clinic of a tertiary referral ophthalmic center in India. Ann Indian Acad Neurol. 2010;13:37–41.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Agarwal A, Vibha D, Prasad K, Bhatia R, Singh MB, Garg A, Saxena R. Predictors of poor visual outcome in patients with idiopathic intracranial hypertension (IIH): an ambispective cohort study. Clin Neurol Neurosurg. 2017;159:13–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India. 2009;57:163–70.PubMedGoogle Scholar
  20. 20.
    Daniels AB, Liu GT, Volpe NJ, Galetta SL, Moster ML, Newman NJ, et al. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol. 2007;143:635–41.PubMedCrossRefGoogle Scholar
  21. 21.
    Ko MW, Chang SC, Ridha MA, Ney JJ, Ali TF, Friedman DI, et al. Weight gain and recurrence in idiopathic intracranial hypertension: a case-control study. Neurology. 2011;76:1564–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Szewka AM, Bruce BB, Newman NJ, Biousse V. Idiopathic intracranial hypertension: relationship between obesity and visual outcomes. J Neuroophthalmol. 2013;33:4–8.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Ooi LY, Walker BR, Bodkin PA, Whittle IR. Idiopathic intracranial hypertension: can studies of obesity provide the key to understanding pathogenesis? Br J Neurosurg. 2008;22:187–94.PubMedCrossRefGoogle Scholar
  24. 24.
    Bruce BB, Kedar S, Van Stavern GP, Corbett JJ, Newman NJ, Biousse V. Atypical idiopathic intracranial hypertension: normal BMI and older patients. Neurology. 2010;74:1827–32.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Manfield JH, Yu KK, Efthimiou E, Darzi A, Athanasiou T, Ashrafian H. Bariatric surgery or non-surgical weight loss for idiopathic intracranial hypertension? A systematic review and comparison of meta-analyses. Obes Surg. 2017;27:513–21.PubMedCrossRefGoogle Scholar
  26. 26.
    Sugerman H, DeMaria E, Felton W, et al. Increased intra-abdominal pressure and cardiac filling pressures in obesity-associated pseudotumor cerebri. Neurology. 1997;49:507–11.PubMedCrossRefGoogle Scholar
  27. 27.
    Banik R. Obesity and the role of nonsurgical and surgical weight reduction in idiopathic intracranial hypertension. Int Ophthalmol Clin. 2014;54:27–41.PubMedCrossRefGoogle Scholar
  28. 28.
    Andrews LE, Liu GT, Ko MW. Idiopathic intracranial hypertension and obesity. Horm Res Paediatr. 2014;81:217–25.PubMedCrossRefGoogle Scholar
  29. 29.
    Dellas C, Schäfer K, Rohm I, et al. Absence of leptin resistance in platelets from morbidly obese individuals may contribute to the increased thrombosis risk in obesity. Thromb Haemost. 2008;100:1123–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Friedman DI. Medication-induced intracranial hypertension in dermatology. Am J Clin Dermatol. 2005;6:29–37.PubMedCrossRefGoogle Scholar
  31. 31.
    Kesler A, Goldhammer Y, Hadayer A, Pianka P. The outcome of pseudotumor cerebri induced by tetracycline therapy. Acta Neurol Scand. 2004;110:408–11.PubMedCrossRefGoogle Scholar
  32. 32.
    Chiu AM, Chuenkongkaew WL, Cornblath WT, et al. Minocycline treatment and pseudotumor cerebri syndrome. Am J Ophthalmol. 1998;126:116–21.PubMedCrossRefGoogle Scholar
  33. 33.
    Greer M. Benign intracranial hypertension. II. Following corticosteroid therapy. Neurology. 1963;13:439–41.PubMedCrossRefGoogle Scholar
  34. 34.
    Neville BG, Wilson J. Benign intracranial hypertension following corticosteroid withdrawal in childhood. Br Med J. 1970;3:554–6.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Deonna T, Guignard JP. Acute intracranial hypertension after nalidixic acid administration. Arch Dis Child. 1974;49:743.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Mushet GR. Pseudotumor and nitrofurantoin therapy [letter]. Arch Neurol. 1977;34:257.PubMedCrossRefGoogle Scholar
  37. 37.
    Feldman MH, Schlezinger NS. Benign intracranial hypertension associated with hypervitaminosis A. Arch Neurol. 1970;22:1–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Saul RF, Hamburger HA, Selhorst JB. Pseudotumor cerebri secondary to lithium carbonate. JAMA. 1985;253:2869–70.PubMedCrossRefGoogle Scholar
  39. 39.
    Shah A, Roberts T, McQueen IN, Graham JG, Walker K. Danazol and benign intracranial hypertension. Br Med J. 1987;294:1323.CrossRefGoogle Scholar
  40. 40.
    Ireland B, Corbett JJ, Wallace RB. The search for causes of idiopathic intracranial hypertension. A preliminary case-control study. Arch Neurol. 1990;47:315–20.PubMedCrossRefGoogle Scholar
  41. 41.
    Giuseffi V, Wall M, Siegel PZ, Rojas PB. Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): a case-control study. Neurology. 1991;41:239–44.PubMedCrossRefGoogle Scholar
  42. 42.
    Wall M. Idiopathic intracranial hypertension. Neurol Clin. 2010;28:593–617.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Biousse V, Bruce BB, Newman NJ. Update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry. 2012;83:488–94.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Fraunfelder FW, Fraunfelder FT, Corbett JJ. Isotretinoin-associated intracranial hypertension. Ophthalmology. 2004;111:1248–50.PubMedCrossRefGoogle Scholar
  45. 45.
    Libien J, Blaner WS. Retinol and retinol-binding protein in cerebrospinal fluid: can vitamin A take the “idiopathic” out of idiopathic intracranial hypertension? J Neuroophthalmol. 2007;27:253–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Libien J, Kupersmith MJ, Blaner W, McDermott MP, Gao S, NORDIC Idiopathic Intracranial Hypertension Study Group, et al. Role of vitamin A metabolism in IIH: results from the idiopathic intracranial hypertension treatment trial. J Neurol Sci. 2017;372:78–84.PubMedCrossRefGoogle Scholar
  47. 47.
    Digre KB, Varner MW, Corbett JJ. Pseudotumor cerebri and pregnancy. Neurology. 1984;34:721–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Huna-Baron R, Kupersmith MJ. Idiopathic intracranial hypertension in pregnancy. J Neurol. 2002;249:1078–81.PubMedCrossRefGoogle Scholar
  49. 49.
    Wardly DE. Intracranial hypertension associated with obstructive sleep apnoea: a discussion of potential etiologic factors. Med Hypotheses. 2014;83:792–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Thurtell MJ, Trotti LM, Bixler EO, Rye DB, Bliwise DL, Newman NJ, et al. Obstructive sleep apnea in idiopathic intracranial hypertension: comparison with matched population data. J Neurol. 2013;260:1748–51.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Wardly D, Wolford LM, Veerappan V. Idiopathic intracranial hypertension eliminated by counterclockwise maxillomandibular advancement: a case report. Cranio. 2017;35(4):259–67.PubMedCrossRefGoogle Scholar
  52. 52.
    Kalyoussef E, Brooks NO, Quraishi H, Turbin R, Frohman L. Idiopathic intracranial hypertension in a child with obstructive sleep apnea cured by tonsillectomy/adenoidectomy. J Neuroophthalmol. 2013;33:413–4.PubMedCrossRefGoogle Scholar
  53. 53.
    Donaldson JO. Cerebrospinal fluid hypersecretion in pseudotumor cerebri. Trans Am Neurol Assoc. 1979;104:196–8.PubMedGoogle Scholar
  54. 54.
    Riggeal BD, Bruce BB, Saindane AM, Ridha MA, Kelly LP, Newman NJ, et al. Clinical course of idiopathic intracranial hypertension with transverse sinus stenosis. Neurology. 2013;80:289–95.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Boulton M, Armstrong D, Flessner M, Hay J, Szalai JP, Johnston M. Raised intracranial pressure increases CSF drainage through arachnoid villi and extracranial lymphatics. Am J Phys. 1998;275(3 Pt 2):889–96.Google Scholar
  56. 56.
    Jacobson DM, Karanjia PN, Olson KA, Warner JJ. Computed tomography ventricular size has no predictive value in diagnosing pseudotumor cerebri. Neurology. 1990;40:1454–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Wall M, Dollar JD, Sadun AA, Kardon R. Idiopathic intracranial hypertension: lack of histologic evidence for cerebral edema. Arch Neurol. 1995;52:141–5.PubMedCrossRefGoogle Scholar
  58. 58.
    Kesler A, Kliper E, Assayag EB, et al. Thrombophilic factors in idiopathic intracranial hypertension: a report of 51 patients and a meta-analysis. Blood Coagul Fibrinolysis. 2010;21:328–33.PubMedCrossRefGoogle Scholar
  59. 59.
    Nagelhus EA, Ottersen OP. Physiological roles of aquaporin-4 in brain. Physiol Rev. 2013;93:1543–62.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Bloch O, Auguste KI, Manley GT, Verkman AS. Accelerated progression of kaolin-induced hydrocephalus in aquaporin-4-deficient mice. J Cereb Blood Flow Metab. 2006;26:1527–37.PubMedCrossRefGoogle Scholar
  61. 61.
    Papadopoulos MC, Manley GT, Krishna S, Verkman AS. Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J. 2004;18:1291–3.PubMedCrossRefGoogle Scholar
  62. 62.
    Dhungana S, Sharrack B, Woodroofe N. Cytokines and chemokines in idiopathic intracranial hypertension. Headache. 2009;49:282–5.PubMedCrossRefGoogle Scholar
  63. 63.
    Kerty E, Heuser K, Indahl UG, Berg PR, Nakken S, Lien S, et al. Is the brain water channel aquaporin-4 a pathogenetic factor in idiopathic intracranial hypertension? Results from a combined clinical and genetic study in a Norwegian cohort. Acta Ophthalmol. 2013;91:88–91.PubMedCrossRefGoogle Scholar
  64. 64.
    Bezerra MLS, Ferreira ACAF, de Oliveira-Souza R. Pseudotumor cerebri and glymphatic dysfunction. Front Neurol. 2018;16(8):734.CrossRefGoogle Scholar
  65. 65.
    Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012;4:147ra111.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Iliff JJ, Goldman SA, Nedergaard M. Clearing the mind: implications of dural lymphatic vessels for brain function. Lancet Neurol. 2015;14:977–9.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Baykan B, Ekizoğlu E, Altıokka Uzun G. An update on the pathophysiology of idiopathic intracranial hypertension alias pseudotumor cerebri. Agri. 2015;27:63–72.PubMedGoogle Scholar
  68. 68.
    Strydom MA, Briers N, Bosman MC, Steyn S. The anatomical basis of venographic filling defects of the transverse sinus. Clin Anat. 2010;23:153–9.PubMedGoogle Scholar
  69. 69.
    Bateman GA, Stevens SA, Stimpson J. A mathematical model of idiopathic intracranial hypertension incorporating increased arterial inflow and variable venous outflow collapsibility. J Neurosurg. 2009;110:446–56.PubMedCrossRefGoogle Scholar
  70. 70.
    Farb RI, Vanek I, Scott JN, et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology. 2003;60:1418–24.PubMedCrossRefGoogle Scholar
  71. 71.
    Friedman DI, McDermott MP, Kieburtz K, Kupersmith M, Stoutenburg A, Keltner JL, Feldon SE, Schron E, Corbett JJ, Wall M, NORDIC IIHTT Study Group, et al. The idiopathic intracranial hypertension treatment trial: design considerations and methods. J Neuroophthalmol. 2014;34:107–17.PubMedCrossRefGoogle Scholar
  72. 72.
    Avery RA. Interpretation of lumbar puncture opening pressure measurements in children. J Neuroophthalmol. 2014;34:284–7.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Lim MJ, Lin JP. The effects of carbon dioxide on measuring cerebral spinal fluid pressure. Childs Nerv Syst. 2009;25:783–4.PubMedCrossRefGoogle Scholar
  74. 74.
    Kupersmith MJ, Sibony PA, Feldon SE, Wang JK, Garvin M, Kardon R, OCT Substudy Group for the NORDIC Idiopathic Intracranial Hypertension Treatment Trial. The effect of treatment of idiopathic intracranial hypertension on prevalence of retinal and choroidal folds. Am J Ophthalmol. 2017;176:77–86.PubMedCrossRefGoogle Scholar
  75. 75.
    Optical Coherence Tomography Substudy Committee, NORDIC Idiopathic Intracranial Hypertension Study Group. Papilledema outcomes from the optical coherence tomography substudy of the idiopathic intracranial hypertension treatment trial. Ophthalmology. 2015;122:1939–45.CrossRefGoogle Scholar
  76. 76.
    Sibony P, Kupersmith MJ, Rohlf FJ. Shape analysis of the peripapillary RPE layer in papilledema and ischemic optic neuropathy. Invest Ophthalmol Vis Sci. 2011;52:7987–95.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Sibony P, Kupersmith MJ, Honkanen R, et al. Effects of lowering cerebrospinal fluid pressure on the shape of the peripapillary retina in intracranial hypertension. Invest Ophthalmol Vis Sci. 2014;55:8223–31.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Wall M. Update on idiopathic intracranial hypertension. Neurol Clin. 2017;35:45–57.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Bidot S, Saindane AM, Peragallo JH, Bruce BB, Newman NJ, Biousse V. Brain imaging in idiopathic intracranial hypertension. J Neuroophthalmol. 2015;35:400–11.PubMedCrossRefGoogle Scholar
  80. 80.
    Bialer OY, Rueda MP, Bruce BB, Newman NJ, Biousse V, Saindane AM. Meningoceles in idiopathic intracranial hypertension. AJR Am J Roentgenol. 2014;202:608–13.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Schlosser RJ, Woodworth BA, Wilensky EM, Grady MS, Bolger WE. Spontaneous cerebrospinal fluid leaks: a variant of benign intracranial hypertension. Ann Otol Rhinol Laryngol. 2006;115:495–500.PubMedCrossRefGoogle Scholar
  82. 82.
    Seth R, Rajasekaran K III, Luong A, Benninger MS, Batra PS. Spontaneous CSF leaks: factors predictive of additional interventions. Laryngoscope. 2010;120:2141–6.PubMedCrossRefGoogle Scholar
  83. 83.
    Bidot S, Bruce BB, Saindane AM, Newman NJ, Biousse V. Asymmetric papilledema in idiopathic intracranial hypertension. J Neuroophthalmol. 2015;35:31–6.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Barkovich AJ, Wippold FJ, Sherman JL, Citrin CM. Significance of cerebellar tonsillar position on MR. AJNR Am J Neuroradiol. 1986;7:795–9.PubMedGoogle Scholar
  85. 85.
    Saindane AM, Bruce BB, Desai NK, Roller LA, Newman NJ, Biousse V. Transverse sinus stenosis in adult patients with Chiari malformation type I. AJR Am J Roentgenol. 2014;203:890–6.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Aiken AH, Hoots JA, Saindane AM, Hudgins PA. Incidence of cerebellar tonsillar ectopia in idiopathic intracranial hypertension: a mimic of the Chiari I malformation. AJNR Am J Neuroradiol. 2012;33:1901–6.PubMedCrossRefGoogle Scholar
  87. 87.
    Tuncel SA, Yılmaz E, Çağlı B, Tekataş A, Çelik Y, Ünlü ME. Lumbar opening pressure and radiologic scoring in idiopathic intracranial hypertension: is there any correlation? Pol J Radiol. 2017;82:701–5.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Schwartz KM, Luetmer PH, Hunt CH, Kotsenas AL, Diehn FE, Eckel LJ, et al. Position-related variability of CSF opening pressure measurements. AJNR Am J Neuroradiol. 2013;34:904–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Dinsmore J, Bacon RC, Hollway TE. The effect of increasing degrees of spinal flexion on cerebrospinal fluid pressure. Anaesthesia. 1998;53:431–4.PubMedCrossRefGoogle Scholar
  90. 90.
    Sithinamsuwan P, Sithinamsuwan N, Tejavanija S, Udommongkol C, Nidhinandana S. The effect of whole body position on lumbar cerebrospinal fluid opening pressure. Cerebrospinal Fluid Res. 2008;5:11.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Wong R, Madill SA, Pandey P, Riordan-Eva P. Idiopathic intracranial hypertension: the association between weight loss and the requirement for systemic treatment. BMC Ophthalmol. 2007;7:15.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Wall M, Johnson CA, Cello KE, Zamba KD, McDermott MP, Keltner JL, NORDIC Idiopathic Intracranial Hypertension Study Group. Visual field outcomes for the idiopathic intracranial hypertension treatment trial (IIHTT). Invest Ophthalmol Vis Sci. 2016;57:805–12.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    tenHove MW, Friedman DI, Patel AD, et al. Safety and tolerability of acetazolamide in the idiopathic intracranial hypertension treatment trial. J Neuroophthalmol. 2016;36:13–9.CrossRefGoogle Scholar
  94. 94.
    Friedman DI, Quiros PA, Subramanian PS, Mejico LJ, Gao S, McDermott M, Wall M, NORDIC IIHTT Study Group. Headache in idiopathic intracranial hypertension: findings from the idiopathic intracranial hypertension treatment trial. Headache. 2017;57:1195–205.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Au JN, Waslo CS, McGwin G Jr, Huisingh C, Tanne E. Acetazolamide induced nephrolithiasis in idiopathic intracranial hypertension patients. J Neuroophthalmol. 2016;36:126–30.PubMedCrossRefGoogle Scholar
  96. 96.
    Celebisoy N, Gokcay F, Sirin H, Akyurekli O. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand. 2007;116:322–7.PubMedCrossRefGoogle Scholar
  97. 97.
    Pollay M, Fullenwider C, Roberts PA, Stevens FA. Effect of mannitol and furosemide on blood brain osmotic gradient and intracranial pressure. J Neurosurg. 1983;59:945–50.PubMedCrossRefGoogle Scholar
  98. 98.
    Keltner JL. Optic nerve sheath decompression. Arch Ophthalmol. 1988;106:1365–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Fonseca PL, Rigamonti D, Miller NR, et al. Visual outcomes of surgical intervention for pseudotumour cerebri: optic nerve sheath fenestration versus cerebrospinal fluid diversion. Br J Ophthalmol. 2014;98:1360–3.PubMedCrossRefGoogle Scholar
  100. 100.
    Obi EE, Lakhani BK, Burns J, Sampath R. Optic nerve sheath fenestration for idiopathic intracranial hypertension: a seven-year review of visual outcomes in a tertiary Centre. Clin Neurol Neurosurg. 2015;137:94–101.PubMedCrossRefGoogle Scholar
  101. 101.
    Gilbert AL, Chwalisz B, Mallery R. Complications of optic nerve sheath fenestration as a treatment for idiopathic intracranial hypertension. Semin Ophthalmol. 2018;33(1):36–41.PubMedCrossRefGoogle Scholar
  102. 102.
    Abubaker K, Ali Z, Raza K, Bolger C, Rawluk D, O’Brien D. Idiopathic intracranial hypertension: lumboperitoneal shunts versus ventriculopaeritoneal shunts-case series and literature review. Br J Neurosurg. 2011;25:94–9.PubMedCrossRefGoogle Scholar
  103. 103.
    Huang LC, Winter TW, Herro AM, et al. Ventriculoperitoneal shunt as a treatment of visual loss in idiopathic intracranial hypertension. J Neuroophthalmol. 2014;34:223–8.PubMedCrossRefGoogle Scholar
  104. 104.
    Ahmed R, Friedman DI, Halmagyi GM. Stenting of the transverse sinuses in idiopathic intracranial hypertension. J Neuroophthalmol. 2011;31:374–80.PubMedCrossRefGoogle Scholar
  105. 105.
    Lai LT, Danesh-Meyer HV, Kaye AH. Visual outcomes and headache following interventions for idiopathic intracranial hypertension. J Clin Neurosci. 2014;21:1670–8.PubMedCrossRefGoogle Scholar
  106. 106.
    Satti SR, Leishangthem L, Chaudry MI. Meta-analysis of CSF diversion procedures and dural venous sinus stenting in the setting of medically refractory idiopathic intracranial hypertension. AJNR Am J Neuroradiol. 2015;36:1899–904.PubMedCrossRefGoogle Scholar
  107. 107.
    Ahmed RM, Wilkinson M, Parker GD, et al. Transverse sinus stenting for idiopathic intracranial hypertension: a review of 52 patients and of model predictions. AJNR Am J Neuroradiol. 2011;32:1408–14.PubMedCrossRefGoogle Scholar
  108. 108.
    Fridley J, Foroozan R, Sherman V, et al. Bariatric surgery for the treatment of idiopathic intracranial hypertension. J Neurosurg. 2011;114:34–9.PubMedCrossRefGoogle Scholar
  109. 109.
    Yri HM, Wegener M, Sander B, et al. Idiopathic intracranial hypertension is not benign: a long-term outcome study. J Neurol. 2011;259:886–94.PubMedCrossRefGoogle Scholar
  110. 110.
    NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee, Wall M, MP MD, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014;311:1641–51.CrossRefGoogle Scholar
  111. 111.
    Storch TG, Layton WM Jr. Teratogenic effects of intrauterine injection of acetazolamide and amiloride in hamsters. Teratology. 1973;7:209–14.PubMedCrossRefGoogle Scholar
  112. 112.
    Worsham F Jr, Beckman EN, Mitchell EH. Sacrococcygeal teratoma in a neonate. Association with maternal use of acetazolamide. JAMA. 1978;240:251–2.PubMedCrossRefGoogle Scholar
  113. 113.
    Havránek P, Hedlund H, Rubenson A, et al. Sacrococcygeal teratoma in Sweden between 1978 and 1989: long-term functional results. J Pediatr Surg. 1992;27:916–8.PubMedCrossRefGoogle Scholar
  114. 114.
    Lee AG, Pless M, Falardeau J, et al. The use of acetazolamide in idiopathic intracranial hypertension during pregnancy. Am J Ophthalmol. 2005;139:855–9.PubMedCrossRefGoogle Scholar
  115. 115.
    Falardeau J, Lobb BM, Golden S, et al. The use of acetazolamide during pregnancy in intracranial hypertension patients. J Neuroophthalmol. 2013;33:9–12.PubMedCrossRefGoogle Scholar
  116. 116.
    Tang RA, Dorotheo EU, Schiffman JS, et al. Medical and surgical management of idiopathic intracranial hypertension in pregnancy. Curr Neurol Neurosci Rep. 2004;4:398–4091.PubMedCrossRefGoogle Scholar
  117. 117.
    Wall M, Falardeau J, Fletcher WA, Granadier RJ, Lam BL, Longmuir RA, Patel AD, Bruce BB, He H, McDermott MP, NORDIC Idiopathic Intracranial Hypertension Study Group. Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension. Neurology. 2015;85:799–805.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Cinciripini GS, Donahue S, Borchert MS. Idiopathic intracranial hypertension in prepubertal pediatric patients: characteristics, treatment, and outcome. Am J Ophthalmol. 1999;127:178–82.PubMedCrossRefGoogle Scholar
  119. 119.
    Rangwala LM, Liu GT. Pediatric idiopathic intracranial hypertension. Surv Ophthalmol. 2007;52:597–617.PubMedCrossRefGoogle Scholar
  120. 120.
    Sheldon C, Paley GL, Xiao R, Kesler A, Eyal O, Ko MW, et al. Pediatric idiopathic intracranial hypertension: age, gender, and anthropometric features at diagnosis in a large, retrospective, multisite cohort. Ophthalmology. 2016;123:2424–31.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Bassan H, Berkner L, Stolovich C, Kesler A. Asymptomatic intracranial hypertension in children. Acta Neurol Scand. 2008;118:251–5.PubMedCrossRefGoogle Scholar
  122. 122.
    Lim MJ, Pushparajah K, Jan W, et al. Magnetic resonance imaging changes in idiopathic intracranial hypertension in children. J Child Neurol. 2010;25:294–9.PubMedCrossRefGoogle Scholar
  123. 123.
    Hartmann AJ, Soares BP, Bruce BB, Saindane AM, Newman NJ, Biousse V, et al. Imaging features of idiopathic intracranial hypertension in children. J Child Neurol. 2017;32:120–6.PubMedCrossRefGoogle Scholar
  124. 124.
    Tovia E, Reif S, Oren A, Mitelpunkt A, Fattal-Valevski A. Treatment response in pediatric patients with pseudotumor cerebri syndrome. J Neuroophthalmol. 2017;37:393–7.PubMedCrossRefGoogle Scholar
  125. 125.
    Xie X, Zhang X, Fu J, Wang H, Jonas JB, Peng X, Beijing iCOP Study Group. Noninvasive intracranial pressure estimation by orbital subarachnoid space measurement: the Beijing intracranial and intraocular pressure (iCOP) study. Crit Care. 2013;24(17):R162.CrossRefGoogle Scholar
  126. 126.
    Saindane AM, Qiu D, Oshinski JN, Newman NJ, Biousse V, Bruce BB, et al. Noninvasive assessment of intracranial pressure status in idiopathic intracranial hypertension using displacement encoding with stimulated echoes (DENSE) MRI: a prospective patient study with contemporaneous CSF pressure correlation. AJNR Am J Neuroradiol. 2018;39:311–6.PubMedCrossRefGoogle Scholar
  127. 127.
    Markey KA, Ottridge R, Mitchell JL, Rick C, Woolley R, Ives N, et al. Assessing the efficacy and safety of an 11β-Hydroxysteroid Dehydrogenase type 1 inhibitor (AZD4017) in the idiopathic intracranial hypertension drug trial (IIH: DT): clinical methods and design for a phase II randomized controlled trial. JMIR Res Protoc. 2017;6:e181.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Hermann EJ, Polemikos M, Heissler HE, Krauss JK. Shunt surgery in idiopathic intracranial hypertension aided by electromagnetic navigation. Stereotact Funct Neurosurg. 2017;95:26–33.PubMedCrossRefGoogle Scholar
  129. 129.
    Chandran A, Pulhorn H, McMahon C. Idiopathic intracranial hypertension VISION (venous intervention versus shunting in IIH for optic nerve disc swelling) trial: patient perspective questionnaire. Br J Neurosurg. 2019;33(1):71–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Virender Sachdeva
    • 1
    Email author
  • Gurcharan Singh
    • 2
  • Gautam Yadav
    • 2
  1. 1.Pediatric Ophthalmology and Neuro-ophthalmology, Nimmagadda Prasad Children’s Eye Care CentreL V Prasad Eye Institute, GMR Varalakshmi CampusVishakhapatnamIndia
  2. 2.L V Prasad Eye Institute, GMR Varalakshmi CampusVishakhapatnamIndia

Personalised recommendations